AcelRx Pharmaceuticals
AcelRx Pharmaceuticals | Therapies for Acute Pain.
Launch date
Employees
Market cap
€13.9m
Enterprise valuation
€14m (Public information from Sep 2024)
Share price
$0.9414 ACRX
Redwood City California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.4m | 2.8m | 1.8m | <1m | <1m | <1m | 7.1m |
% growth | 137 % | (48 %) | (37 %) | (63 %) | 5 % | (72 %) | 3582 % |
EBITDA | (37.1m) | (30.8m) | (30.2m) | - | - | - | - |
% EBITDA margin | (684 %) | (1094 %) | (1704 %) | - | - | - | - |
Profit | (40.4m) | (35.1m) | 47.8m | (18.4m) | (18.9m) | (25.9m) | (23.5m) |
% profit margin | (746 %) | (1246 %) | 2696 % | (2826 %) | (2769 %) | (13399 %) | (330 %) |
EV / revenue | 18.7x | 27.2x | 10.5x | 19.1x | 25.9x | 91.4x | 2.5x |
EV / EBITDA | -2.7x | -2.5x | -0.6x | - | - | - | - |
R&D budget | 4.0m | 4.1m | 5.2m | - | - | - | - |
R&D % of revenue | 74 % | 145 % | 293 % | - | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $20.8m | Post IPO Debt | |
N/A | $10.0m | Post IPO Equity | |
$40.0m | Debt | ||
$25.0m | Post IPO Debt | ||
N/A | $27.5m | Post IPO Equity | |
N/A | $14.0m | Post IPO Equity | |
* | N/A | $7.5m | Post IPO Equity |
* | N/A | $10.0m | Post IPO Equity |
* | N/A | $8.0m | Debt |
Total Funding | €13.5m |
Recent News about AcelRx Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by AcelRx Pharmaceuticals
EditACQUISITION by La jolla Pharmaceutical Jul 2020